CapForce Inc. · OTC:CFOR

CapForce — Opgen — Investor Presentation (January 2016)

28 slides from CapForce's investor presentation, Jan 12, 2016

  1. Slide 1: OpGen Corporate Presentation

    ISS ® OpGen Corporate Presentation “Precision Medicine Solutions for January 2016 Combatting Infectious Disease” (©2016 Open, f@OpGen’

  2. Slide 2: Forward-Looking Statement

    Forward-Looking Statement This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward looking ‘statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, anal

  3. Slide 3: Company Overview

    Company Overview Driving precision medicine solutions for combatting infectious disease with the power of bioinformatics and clinical diagnostics Our Business Our Technology Proprietary DNA testing and advanced bioinformatics to guide patient Platform care decisions and match drugs with infections S

  4. Slide 4: Antibiotic Resistance — A Growing Concern

    | Antibiotic Resistance — A Growing Concern llinesses and 23,000 deaths are caused annually in the United States alone! 2 million $20 billion In excess direct health care costs 2 People are expected to die prematurely because of drug resistance over the next 35 years if antimicrobial drug resistance

  5. Slide 5: Policy Makers are Taking Decisive Action

    | Policy Makers are Taking Decisive Action FY 2016 budget includes $1B to combat drug resistant infections 0201 opm ne 5 f@OpGen

  6. Slide 6: OpGen Suite of Solutions

    | OpGen Suite of Solutions Actionable, precise diagnostics powered by surveillance data Rapid Diagnostics What pathogen is QuickFISH" causing the infection? Powered by PUA Technology Rapid Pathogen ID which antbiotisare = @ACUITAS* $760K appropriate to treat the infection? 12X Fastel 4 Hour Antibiot

  7. Slide 7: Large Precision Medicine Opportunity

    [Large Precision Medicine Opportunity Global Hospital Acquired Infection Testing Revenue 2012 2,183.2 $2B Global Market 19% CAGR: One of the fastest growing U.S. molecular diagnostic segments Multiple high-acuity patient types Total Urinary Tract Surgical site Preumonia Bloodstream MRSA Others Infec

  8. Slide 8: Experienced Management Team

    Experienced Management Team Evan Jones EXDIGENE Pruner Chairman & Chief Executive Officer QP OUNoATION Wreracyre Kevin Krenitsky, M.D. FOUNDATION President @ MEDICINE Timothy Dec FORTRESS Chief Financial Ofer P ¢ Robert McG. Lilley ‘ Chief Commercial Officer bee EDIGENE —AULUTEL Vadim Sapiro eid J.

  9. Slide 9: Merck GHI Investment

    Merck GHI Investment = Merck Global Health Investment Fund — Invests where Merck expertise can accelerate revenue growth and enhance value creation — GHl often invests in disease areas where Merck is a major global market leader such as hospital acquired infections = $6 million investment = Pro rata

  10. Slide 10: Precision solutions transforming a years old treatment paradigm

    a al = oer Precision solutions transforming a 50 year old treatment paradigm

  11. Slide 11: Introducing Precision Medicine

    Introducing Precision Med ae vs. Analog The Golden Hour for antibiotic | Conventional microbiology largely decision-making 1 hour tests needed to impact tial therapy de + MDRO rates amplify empiric use of “Big Gun” antibioti * Critical need for clinical decision support tools to aid antibiotic selec

  12. Slide 12: Breaking the Acute Care Treatment Paradigm

    | Breaking the Acute Care Treatment Paradigm iP Actual Case Study: MDRO infected patient Antibiotic Coverage at Gram Negative Rods Patient Died Admission: Detected * Gram Positive * Grant Negative Fluoroquinolone * Anaerobe iat K, Pneumonia (MALDI) 48 Hours. Resistant to CRE Imipenem Confirmed No In

  13. Slide 13: Rapid Antibiotic Resistance Information

    Rapid Antibiotic Resistance Information One Hour Disruptive Paradigm In Development OpGen’s proprietary technology Powers pathogen identification and resistance gene profiling Informed by smart cloud-based clinical database that learns new molecular profiles to aid initial antibiotic selection and c

  14. Slide 14: Acuitas Lighthouse — Evergreen Database

    [ Acuitas Lighthouse — “Evergreen” Database Continual global sample pathogen feed from OpGen laboratory clients and hospital customers Comprehensive testing ©ACUITAS” Surveillance data Resistome genotyping Whole genome sequencing Pathogen ID Phenotypic testing . 7 Rapid IVD Platform! QuickFISH = Pat

  15. Slide 15: Competitive Landscape

    Competitive Landscape Rapid organism ID & AST methods Analytical method time to results [@OpGev ID & Molecular AST by Rapid Array PCR ff 1 Hour, Genotype Resistance/Susceptibility Interpretation [@OpGen QuickFisH io | 30 Minutes? [a OpGev uickrish ID/ MRSA AST 45 Hours, Organism ID, phenotypic AST?

  16. Slide 16: Acuitas Lighthouse Data Opportunities

    | Acuitas Lighthouse™ Data Opportunities > Powering a 1-hour diagnosis YS * Molecular susceptibility testing data at scale + Smart cloud-based system learns new molecular profiles + Powers Acuitas® antibiotic selection/decision making tool $2 Billion Rapid Diagnostics & Antimicrobial Stev , fe] Acce

  17. Slide 17: Acuitas Lighthouse MDRO Screening & Surveillance

    Acuitas Lighthouse™ MDRO Screening & Surveillance Providing high resolution organism ID and matching drugs to infections MDRO Gene Test CR Elite Test Rapid screening & Confirm CRE presence surveillance for infection Whole Genome Sequence Resistome Test Analysis Isolate genotyping High resolution ana

  18. Slide 18: Acuitas Lighthouse Used in HARP-DC MDRO Surveillance Initiative

    Acuitas Lighthouse Used in HARP-DC MDRO Surveillance Initiative in Collaboration with CDC Individual hospital & patient reporting, geospatial analysis Advanced analytics engine Direct connection to LIMS. database Cloud-based HIPAA compliant. Security + End-to-end encryption (database, connectors, br

  19. Slide 19: Deep Pipeline of Current and Future Products

    Deep Pipeline of Current and Future Products | ie ha | Commercial Development Phase Validation Automation, 4H 2017 | sH2017 MORO Gene Test, Resistome, DNA‘ ce > 2015 | | | | Multiplex Rapid Molecular or Lighthouse™ Data Warehouse & Portal 2015 2017 Anibit nah | 0201 ogee 0 f@OpGen’

  20. Slide 20: QuickFISH Rapid Molecular Pathogen ID

    QuickFISH™ Rapid Molecular Pathogen ID * Established, market leading Rapid ID products = AdvanDx QuickFISH™ family of products — Rapid blood culture ID tests — FDAcleared, CE marked * Staphylococcus, Enterococcus, Gram-negative bacteria, Candida = Rapid MRSA antibiotic susceptibility test = Over 100

  21. Slide 21: Case Study: Winter Haven Hospital

    Case Study: Winter Haven Hospital Demonstrated Clinical Utility and Cost Effectiveness Rapid Staph ID Application via QuickFISH Resulted in: = $764K annual savings a1 @ = 30% reduction in length of stay = 65% decrease in days on Vancomycin F ven (2.5 days to 0.9 days) 4 WT al = 90% reduction in path

  22. Slide 22: Building a Leading Molecular Information Business

    Building a Leading Molecular Information Business Customer Focus * Healthcare providers * Physicians * Patients * Pharma partners CORPORATE EXPERTISE Sales & Marketing Operations & Finance Regulatory & Compliance (©2016 opGen, ne

  23. Slide 23: Commercial Launch Plans

    |Ccommercial Launch Plans First global molecular diagnostics company providing pathogen and resistance Driving Value in 2016 and Beyond data to inform critical antibiotic treatment decisions Mature commercial team Strategic co-marketing relationships Expanded distributor network Global revenues with

  24. Slide 24: Company Timeline

    Company Timeline FALL OPGEN recapitalized, new CEO, focus on developing and 2013 commercializing precision medicine solutions for combating infectious disease MAY _ oPGEN IPO to strengthen balance sheet 2015 and provide growth capital JULY + Merck GHI investment 2015 + AdvanDx rapid diagnostics acqu

  25. Slide 25: Q3 FY 2015 Highlights

    | Q3 FY 2015 Highlights Select income statement data (000’s) Product sales Collaboration revenue Total revenue Gross margin"? Operating expense! Operating loss! 932014 $356 $478 $834 70% $2,163 ($1,581) YOv% Change 166.9% (94.1%) 17.6% (39.0%) 129.3% 194.4% Select balance sheet data (00's) Cash and

  26. Slide 26: Next Steps

    Next Steps g Digital DNA analysis revolutionizing microbiology + 30-60 minute rapid tests + 6 million base pair DNA analysis + Data analysis software + Highly robust scalable solutions Expand pharma and health system relationships Strengthen global distribution network Accelerate development of Acui

  27. Slide 27: Company Highlights

    Company Highlights Nasdaq:OPGN World-class team developing one of the largest hospital diagnostic and informatics markets Rapid molecular information to inform management of patients with bacterial infections * Global health crisis of antibiotic resistance = Large and growing market opportunity = Me

  28. Slide 28: OpGen

    ISS ® OpGen Corporate Presentation “Precision Medicine Solutions for January 2016 Combatting Infectious Disease” sangonse Ta@OpGen

Opgen — Investor Presentation (January 2016) on 6ix